RxDoctor Payments DataLook up a doctor →

Darren Goff, MD

Obstetrics & Gynecology · Oklahoma City, OKNPI 1700858347

Payments from drug & device makers

$9,853in general payments, 2019–2025

Across 399 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Gynesonics, Inc.$1K
  • Mayne Pharma Commercial LLC$515
  • Pfizer$494
  • Exeltis, USA Inc.$426
  • Daiichi Sankyo Inc.$380
  • plus $5K from 49 others

What the payments were for

  • Food & beverage$9,65398%
  • Education$1642%
  • Gifts$350%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,853 in reported general payments places this provider in the 90th percentile of 396 obstetrics & gynecology providers in Oklahoma.

See all obstetrics & gynecology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$12,337
Medicare patients
79
Services billed
137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProgesteroneProgesterone, Micronized207$6,983
Estradiol111$3,206
EstrogelEstradiol13$2,032
Estradiol (Twice Weekly)Estradiol15$1,610
Estradiol (Once Weekly)Estradiol14$1,535
Norethindrone Acetate13$1,311
Liothyronine Sodium19$535
Gabapentin13$267
Testosterone Cypionate22$246
Naproxen21$195
Ondansetron OdtOndansetron16$158
Bupropion Hcl SrBupropion Hcl13$149
Sertraline Hcl15$146
Levothyroxine Sodium31$125
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Ascend Therapeutics US, LLCEstrogel$51$2,03213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 396 obstetrics & gynecology providers in Oklahoma.

Other obstetrics & gynecology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →